- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04543539
IN.PACT™ AV Access Post-Approval Study (PAS002)
February 12, 2024 updated by: Medtronic
Long-term safety will be summarized
Study Overview
Status
Recruiting
Conditions
Detailed Description
The purpose of this study is to evaluate the long-term safety of the IN.PACT™ AV Access Drug Coated Balloon (DCB) for treatment of subjects presenting with de novo or non-stented restenotic obstructive lesion of native arteriovenous dialysis fistulae (AVF) in the upper extremity.
Patients will be followed for five years.
The IN.PACT™ AV Access PAS 002 is required by the Food and Drug Administration (FDA) as a condition of product approval.
This study is conducted within Medtronic's post market surveillance platform.
Study Type
Observational
Enrollment (Estimated)
240
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: PSR Study Team
- Phone Number: 763-526-5668
- Email: rs.productsurveillanceregistry@medtronic.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars-Sinai Heart Institute
-
Contact:
- Donald T Baril, MD
-
Stanford, California, United States, 94301
- Recruiting
- Stanford University Medical Center
-
Contact:
- Ronald Dalman, MD
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Recruiting
- YALE New Haven Hospital
-
Contact:
- Britt Tonnessen, MD
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Recruiting
- MedStar Washington Hospital
-
Contact:
- Nelson Bernardo, MD
-
-
Florida
-
Naples, Florida, United States, 34102
- Recruiting
- NCH Healthcare System
-
Contact:
- Alvaro J Zamora, MD, FACS
-
Pensacola, Florida, United States, 32504
- Terminated
- Coastal Vascular and Interventional
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Terminated
- University of Iowa
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan Health System - University Hospital
-
Contact:
- Karthik Ramani, MD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Sanjay Misra, MD
-
-
New Jersey
-
Teaneck, New Jersey, United States, 07666
- Recruiting
- Holy Name Medical Center
-
Contact:
- John Rundback, MD
-
-
New York
-
Albany, New York, United States, 12084
- Terminated
- Albany Medical College
-
New York, New York, United States, 10029
- Recruiting
- The Mount Sinai Hospital
-
Contact:
- Kim Sung Yup, MD
-
Staten Island, New York, United States, 10305
- Recruiting
- Staten Island University Hospital
-
Contact:
- Vincent Gallo, MD
-
-
North Carolina
-
Pinehurst, North Carolina, United States, 28374
- Recruiting
- FirstHealth of the Carolinas
-
Contact:
- Clint Atkinson, MD
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health & Science University Hospital
-
Contact:
- Khashayar Farsad, MD
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17602
- Recruiting
- Lancaster General Hospital
-
Contact:
- Meghan Dermody, MD
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- Recruiting
- MUSC Health Dialysis Access Institute
-
Contact:
- John Aruny, MD
-
Spartanburg, South Carolina, United States, 29303
- Recruiting
- Spartanburg Regional Medical Center
-
Contact:
- Ari Kramer, MD
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Recruiting
- University of Virginia Medical Center
-
Contact:
- Daniel Sheeran, MD
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53713
- Recruiting
- University of Wisconsin-Madison - Meriter Hospital
-
Contact:
- Micah Chan, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The study population includes patients that will have an angioplasty with the IN.PACT™ AV Paclitaxel-Coated PTA Balloon Catheter (IN.PACT™ AV DCB).
Description
Primary Cohort Inclusion Criteria:
- Patient is ≥ 21 years of age
- Patient has a mature native AV fistula created ≥ 60 days prior to the index procedure
- Patient has a de novo and/or non-stented restenotic lesion located between the arteriovenous anastomosis and axillosubclavian junction
- Patient has a target lesion or a tandem lesion that is ≤ 100 mm in length (by visual estimate) Note: Tandem lesions may be included provided they meet all of the following criteria: a. Separated by a gap of ≤ 30 mm (3 cm), b. Total combined lesion length, including 30 mm gap, ≤ 100 mm, c. Able to be treated as a single lesion
- Patient has a target vessel diameter of 4.0 - 12.0 mm (by visual estimate)
- Patient underwent successful crossing of the target lesion with the guide wire and pre-dilatation with a PTA balloon defined as: Residual stenosis of ≤ 30% AND Absence of a flow limiting dissection or perforation AND No extravasation requiring treatment
Primary Cohort Exclusion Criteria:
- Women who are breastfeeding, pregnant, or are intending to become pregnant, or men intending to father children
- Patient is receiving immunosuppressive therapy
- Patient has an infected AV access or systemic infection
- Patient with hemodynamically significant central venous stenoses that cannot be successfully treated prior to treatment of the target lesion
- Patient with target lesion located central to the axillosubclavian junction
- Patient has significant arterial inflow lesion requiring treatment more than 2 cm upstream from the anastomosis in the AV access
- Patient has presence of pseudoaneurysm or aneurysm requiring treatment at the lesion site
- Target lesion is located within a bare metal or covered stent
- Patients with known allergies or sensitivities to paclitaxel
- Patient with known contraindication, including allergic reaction, or sensitivity to contrast material that cannot be adequately pre-treated
- Patient who cannot receive recommended antiplatelet and/or anticoagulant therapy
- Patient is enrolled in another investigational drug, device, or biologic study and has not completed the primary endpoint, or was previously enrolled in this study
- Patient has a co-morbid condition that, in the judgment of the Investigator, may cause him/her to be non-compliant with the protocol or confound the data interpretation
- Patient has an active COVID-19 infection with ongoing sequela at enrollment or hospitalization for treatment of COVID-19
Inclusion Criteria for Extended Cohort:
- Patient is ≥ 21 years of age
Exclusion Criteria for Extended Cohort:
- Patient has an active COVID-19 infection with ongoing sequela at enrollment or hospitalization for treatment of COVID-19
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
IN.PACT™ AV Access PAS Primary Cohort
The primary cohort consists of enrolled subjects treated with the IN.PACT™ AV DCB according to labeling requirements who meet the inclusion/exclusion criteria for the primary cohort.
|
For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.
|
IN.PACT™ AV Access PAS Extended Cohort
The extended cohort consists of enrolled subjects who do not meet the eligibility criteria for the primary cohort and receive the IN.PACT™ AV DCB device for treatment of stenosis in the AV circuit.
|
For treatment of stenosis in the AV circuit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Infection and Infestations Serious Adverse Events
Time Frame: Through 12 months post-index procedure
|
Demonstrate Infection and Infestations Serious Adverse Events, including pneumonia, meets the performance goal of 30% in the primary cohort.
|
Through 12 months post-index procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality Rate
Time Frame: Through 1, 2, 3, 4, and 5 years post-index procedure
|
Determine mortality rate
|
Through 1, 2, 3, 4, and 5 years post-index procedure
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Extended Cohort - Characterize Infections and Infestations Serious Adverse Events
Time Frame: Through 1-year and all-cause mortality through 5-years post-index procedure
|
Characterize infections and infestations Serious Adverse Events, including pneumonia.
|
Through 1-year and all-cause mortality through 5-years post-index procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 13, 2020
Primary Completion (Estimated)
February 1, 2025
Study Completion (Estimated)
February 1, 2029
Study Registration Dates
First Submitted
September 2, 2020
First Submitted That Met QC Criteria
September 2, 2020
First Posted (Actual)
September 10, 2020
Study Record Updates
Last Update Posted (Estimated)
February 14, 2024
Last Update Submitted That Met QC Criteria
February 12, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IN.PACT™ AV Access PAS002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fistula
-
University Hospital, AkershusUniversity Hospital, Linkoeping; Region Örebro County; Uppsala University HospitalCompletedPerianal FistulaNorway
-
Mayo ClinicWithdrawnBronchoesophageal Fistula | Tracheoesophageal Fistula | Tracheoesopharyngeal FistulaUnited States
-
London North West Healthcare NHS TrustCompletedFistula in Ano | Ano FistulaUnited Kingdom
-
Rush University Medical CenterTerminatedRectal Fistula | Anal Fistula | Fistula in Ano | Transsphincteric FistulaUnited States
-
Zagazig UniversityCompletedTranssphincteric Anal FistulaEgypt
-
William A. Faubion, M.D.CompletedPerianal Fistula | Cryptoglandular Perianal Fistula | Crohn's Perianal FistulaUnited States
-
Konstantinos TsimogiannisSuspendedFistula in Ano | Transsphincteric Anal FistulaSweden
-
Tehran University of Medical SciencesRecruitingFistula PerianalIran, Islamic Republic of
-
Sykehuset Innlandet HFWithdrawn
-
University of MalayaCompleted
Clinical Trials on IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Seung-Whan Lee, M.D., Ph.D.Active, not recruitingCatheterization, Peripheral | Popliteal Artery | Angioplasty, Balloon | Femoral ArteryKorea, Republic of
-
Medtronic EndovascularCompletedFistula | Arteriovenous Fistula | Arteriovenous Fistula Stenosis | Arteriovenous Fistula OcclusionNew Zealand, United States, Japan
-
Urotronic Inc.CompletedStricture UrethraUnited States
-
Medtronic EndovascularCompletedPeripheral Arterial Disease (PAD)Germany
-
Chinese PLA General HospitalUnknown
-
Shanghai Zhongshan HospitalRecruitingTakayasu ArteritisChina
-
Seoul National University HospitalUnknownKor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance DatabaseCoronary Artery Disease | Drug-coated Balloon | Drug-eluting Stents
-
Medtronic EndovascularCompletedPopliteal Artery Stenosis | Popliteal Artery Occlusion | Femoral Artery Occlusion | Femoral Artery StenosisUnited States
-
Julie DawsonActive, not recruitingIschaemic Heart DiseaseUnited Kingdom